Navigation Links
Fluxion Biosciences Receives National Cancer Institute Grant for Development of ERASE-Seq Liquid Biopsy Technology
Date:2/27/2019

Fluxion Biosciences, a leading developer of precision solutions for life science research and diagnostics, today announced that it has received a National Cancer Institute grant for further development of its ERASE-Seq liquid biopsy technology. The Phase I grant will have a duration of 9 months, with clinical support from the lab of Dr. Omar Mian at the Cleveland Clinic.

Liquid biopsies offer the potential to improve treatment of cancer by providing affordable, non-invasive detection of actionable cancer mutations from a blood sample. However, the relative abundance of cancer DNA in blood is extremely low, and below the detection threshold for most assays. Analytical and clinical results have demonstrated that ERASE-Seq provides superior results compared to competitive approaches for sequencing circulating tumor DNA (ctDNA) isolated from blood.

The NCI project includes three main aims: 1) improvements to and validation of the ERASE-Seq bio-informatic algorithms to improve detection sensitivity and specificity, 2) automation of the ERASE-Seq data analysis pipeline, and 3) measuring sensitivity and accuracy of ERASE-Seq to competitive sequencing approaches and to an established “gold standard” technique using cancer patient blood samples.

“We are honored to receive this NCI grant and excited to develop the capabilities of our ERASE-Seq liquid biopsy”, stated Jeff Jensen, CEO. "Liquid biopsies offer tremendous promise, but advances are needed to improve the sensitivity and accuracy of these tests. ERASE-Seq offers the potential to deliver on the promise of cancer precision medicine: the right treatment for the right patient at the right time. We look forward to collaborating with Cleveland Clinic on this important program.”

Dr. Mian, Assistant Professor of Radiation Oncology at Cleveland Clinic, stated, “This collaboration demonstrates the innovation expected of a Small Business Innovative Research grant. It will provide the basis for the first ctDNA diagnostic for hepatocellular carcinoma, effectively changing the way the disease is diagnosed in the clinic. Additionally, if successful this will introduce researchers in other areas of oncology to a powerful method for ctDNA variant analysis.”

About Fluxion Biosciences

Fluxion’s liquid biopsy solutions are revolutionizing how cancer is detected and treated. Fluxion’s pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System, ERASE-Seq ultra-sensitive variant caller, and the Spotlight 59 NGS Oncology Panel for cancer mutation detection from cell-free circulating tumor DNA. Fluxion’s technologies are used globally by leading cancer centers developing new tests for early cancer detection and patient monitoring. For more information about Fluxion's liquid biopsy capabilities, visit liquidbiopsy.fluxionbio.com.

Read the full story at https://www.prweb.com/releases/fluxion_biosciences_receives_national_cancer_institute_grant_for_development_of_erase_seq_liquid_biopsy_technology/prweb16127477.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Inflection Biosciences licenses preclinical oncology programs from the CNIO
2. Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation
3. Springer will publish lecture series with the Mathematical Biosciences Institute
4. Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras
5. Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies
6. The new Africa -- green shoots in biosciences
7. Pressure BioSciences Closes Additional $745,000 of $5 Million PIPE; Funding Received to Date Exceeds $4,000,000
8. ACEA Biosciences Introduces an Exploratory xCELLigence® RTCA S16 Instrument
9. ACEA Biosciences Releases New Version of NovoExpress® Flow Cytometry Software.
10. ACEA Biosciences Launches xCELLigence® RTCA Software Pro to Further Enhance Immuno-Oncology Experimental Design and Analysis
11. Tosoh Bioscience LLC invests in Semba Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics Biomedical (ABM), a leading ... for not only the products and treatments developed, but also the dedicated team ... All the brands built by ABM have received several honors already for 2020, ...
(Date:7/1/2020)... ... 01, 2020 , ... Cure Glioblastoma, a registered 501(c)(3) nonprofit ... aggressive adult brain cancer—announced today the appointments of its first Senior Fellows: John ... the organization’s initiatives and overall vision. , "Senior Fellows are more than advisors; ...
(Date:6/23/2020)... FREDERICK, Md. (PRWEB) , ... ... ... a leading provider of gene-to-protein and monoclonal antibody development services, today announced ... of protein-based products and services to the pharmaceutical, diagnostics, and research industries. ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... ... June 30, 2020 , ... ... announced that the launch of a new clinical diagnostics immuno-oncology service, ... tumor microenvironment (TME). , “Flagship’s TissueInsight is a service that aids pathologists, ...
(Date:6/28/2020)... ... June 25, 2020 , ... With the COVID-19 pandemic impacting ... treatment. In an effort to better understand the cellular responses to COVID-19, the ... dataset portraying therapeutic compound effects from over 1,600 approved and referenced molecules on ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... solutions providers, today announced its strong opposition to the recently introduced bicameral ... a blanket ban on most federal use of nearly all biometric and related ...
(Date:6/23/2020)... Fla. (PRWEB) , ... June 23, 2020 , ... ... enabled solutions in complex indoor environments, announced today that Derek Fournier has been ... role of Chairman of the Board, effective immediately. , “DeCurtis Corporation has ...
Breaking Biology Technology: